Last update Aug. 19, 2022
Very Low Risk
We do not have alternatives for Nimodipine since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Nimodipine in other languages or writings:
Nimodipine belongs to this group or family:
Main tradenames from several countries containing Nimodipine in its composition:
|Oral Bioavail.||16 (3 - 30)||%|
|Protein Binding||97 - 99||%|
|Tmax||0.5 - 1||hours|
|T½||1.1 - 1.7||hours|
|M/P ratio||0.06 - 0.3||-|
|Relative Dose||0.001 - 0.1||%|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a dihydropyridine calcium channel blocker with special action on cerebral blood vessels. It is used in the prevention and treatment of ischemic neurological deficits after subarachnoid hemorrhage due to intracranial aneurysm rupture. Oral or intravenous administration.
Excreted into breast milk in a non-significant amount. (Carcas 1996, Tonks 1995)
Because of pharmacokinetic data (high protein-binding capacity and low oral bioavailability) the observed low excretion into breast milk would be explained.
Nimodipine does not alter secretion of Prolactin. (Formisano 1991, Haitas 1986)
Several medical societies and expert authors consider the use of this medication possible during breastfeeding. (Hale, LactMed, Malachias 2016, Briggs 2015, Schaefer 2015)